Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Man, Caroline De
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Nov 2022 - Nov 2022: Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Jun 2022 - Jun 2022: Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 May 2022 - May 2022: Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 More	Recruiting	3	350	Europe, Canada, US, RoW	Selinexor, KPT-330, Placebo, Ruxolitinib	Karyopharm Therapeutics Inc	Myelofibrosis	09/25	03/28
Nadiminti, Kaylan
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Nov 2022 - Nov 2022: Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Jun 2022 - Jun 2022: Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 May 2022 - May 2022: Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 More	Recruiting	3	350	Europe, Canada, US, RoW	Selinexor, KPT-330, Placebo, Ruxolitinib	Karyopharm Therapeutics Inc	Myelofibrosis	09/25	03/28